23andMe, once a trailblazer in consumer DNA testing, announced a 40% reduction in its workforce this week, laying off over 200 employees and shutting down its therapeutics division. The company is grappling with financial turmoil and fallout from a major data breach that exposed the personal information of nearly seven million users last year. This restructuring marks a pivotal moment as 23andMe redefines its focus in an increasingly competitive and scrutinized industry. The layoffs follow a …
23andMe Cuts 40% of Workforce Amid Financial Struggles and Data Security IssuesRead More